Back to results
US 2009/0221533 A1Published application
Method of treating fatty liver disease
AssigneeChildren's Medical Center Corporation
InventorsMark Puder, Marsha A. Moses
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeChildren's Medical Center Corporation
InventorsMark Puder, Marsha A. Moses
Estimating the term…
The present invention relates to a method for treating a fatty liver disease or disorder in a patient in need thereof. The method comprises administering at least one matrix metalloproteinase (“MMP”) inhibitor to the patient. Fatty liver disease or disorders include, for example, NAFLD, NASH, ALD, fatty liver associated with chronic hepatitis infection, TPN, steroid treatment, tamoxifen treatment, gastrointestional operations, diabetes and Reye's Syndrome. The method is particularly useful when the fatty liver disease is associated with TPN and the patient is an infant or when the patient is obese. MMP inhibitors useful in the present invention include, for example, Marimastat, tetracyclines, Prinomastat, Batimastat, BAY 12-9566, AG3340, BMS-275291, Neovastat, BB-3644, KB-R7785, TIMP1, TIMP2, doxycycline, minocycline, RS-130,830; CGS 27023A, Solimastat, Ro 32-3555, BMS-272591, and D2163. Marimastat is a preferred MMP inhibitor.
A method for treating and/or preventing a fatty liver disease or disorder in a patient in need thereof, comprising selecting a patient in need of treatment and administering at least one matrix metalloproteinase (“MMP”) inhibitor to said patient.
Use of a matrix metalloproteinase inhibitor in the manufacture of a medicament for the treatment and/or prevention of a fatty liver disease or disorder.
Dependencies are inferred from the claim text.